Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead
This article was originally published in The Pink Sheet Daily
Executive Summary
Rather than partner its implantable formulation of exenatide, the biotech turned to hedge funds and other non-traditional investors for the year’s largest round of private capital. The deal enables Intarcia to begin Phase III trials on lead program ITCA-650 for type 2 diabetes, which it believes could be a blockbuster.